CD8A and neoplasm: To exert antitumor responses, CD4+ and CD8+ T cells that are specific to tumor antigens must receive adequate stimuli through the T cell receptor (TCR) via intimate interaction with DCs that display the antigenic peptide–MHC complex in the priming phase and subsequent effector phases [30,31].